Clarity Pharmaceuticals Future Growth

Future criteria checks 0/6

Clarity Pharmaceuticals is forecast to grow earnings and revenue by 46% and 115.2% per annum respectively. EPS is expected to grow by 45.1% per annum. Return on equity is forecast to be -4.5% in 3 years.

Key information

46.0%

Earnings growth rate

45.1%

EPS growth rate

Pharmaceuticals earnings growth	32.0%
Revenue growth rate	115.2%
Future return on equity	-4.5%
Analyst coverage	Low
Last updated	15 May 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

CHIA:CU6 - Analysts future estimates and past financials data (AUD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2026	66	10	42	43	2
6/30/2025	N/A	-49	-49	-49	2
6/30/2024	N/A	-37	-34	-34	2
12/31/2023	9	-31	-38	-38	N/A
9/30/2023	10	-28	-33	-33	N/A
6/30/2023	10	-25	-28	-27	N/A
3/31/2023	10	-23	-24	-24	N/A
12/31/2022	9	-21	-21	-21	N/A
9/30/2022	8	-23	-17	-17	N/A
6/30/2022	6	-24	-14	-13	N/A
3/31/2022	6	-21	-13	-13	N/A
12/31/2021	5	-19	-12	-12	N/A
9/30/2021	4	-15	-10	-10	N/A
6/30/2021	3	-10	-8	-8	N/A
3/31/2021	3	-9	-7	-7	N/A
12/31/2020	3	-9	-7	-7	N/A
9/30/2020	3	-8	-7	-7	N/A
6/30/2020	3	-7	-7	-7	N/A
6/30/2019	3	-4	-4	-4	N/A
6/30/2018	2	-2	-2	-1	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CU6 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CU6 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CU6 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CU6 is forecast to have no revenue next year.

High Growth Revenue: CU6 is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CU6 is forecast to be unprofitable in 3 years.

Clarity Pharmaceuticals Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

No longer forecast to breakeven

Recent updates

New minor risk - Shareholder dilution

Clarity Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 100.64532 million.

Clarity Pharmaceuticals Ltd has filed a Follow-on Equity Offering in the amount of AUD 100.64532 million.

Clarity Pharmaceuticals Announces the Successful Completion of Cohort 3 and Advancement to Cohort 4, the First Multi-Dose Cohort in the SECuRE Trial

Clarity Pharmaceuticals Ltd. Announces Additional COBRA Results: SAR-bisPSMA Detects Lesions in the 2-Millimetre Range

New major risk - Financial position

Clarity Pharmaceuticals Ltd Announces Resignation of Non-Executive Directors

Clarity Pharmaceuticals Announces First Patient Dosed in Registrational Phase III Prostate Cancer Trial with Cu-64 SAR-BispsMA

Clarity Pharmaceuticals Ltd. Announces First Patient with Metastatic Prostate Cancer to Receive 2 Doses of Cu-67 SAR-bisPSMA Achieves Undetectable PSA Level

Clarity Pharmaceuticals Ltd Commences Registrational Phase III Clarify Trial in Prostate Cancer

No longer forecast to breakeven

Clarity Pharmaceuticals Announces Successful Completion of First Stage of Cohort 3 of Phase I/IIa Theranostic Trial, SECuRE

Clarity Pharmaceuticals Announces Recruitment Target Achieves for Phase II Sar-Bombesin Prostate Cancer Trial

Clarity Pharmaceuticals and PSI CRO AG Kick Off SAR-BispsMA Phase III

Clarity Pharmaceuticals Ltd, Annual General Meeting, Nov 23, 2023

Clarity Pharmaceuticals Ltd, Annual General Meeting, Nov 23, 2023

Clarity Pharmaceuticals Announces the Dosing of the First Patient in Its Theranostic (64) Cu Sar-Bombesin Phase I/Ii Trial in Metastatic Castrate Resistant Prostate Cancer Trial in Metastatic Castrates Resistant Prostate Cancer (Mcrpc)

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Clarity Pharmaceuticals Announces Successful Completion of Cohort 2 and Advancement to Cohort 2 of Theranostic Trial, Secure

Clarity Pharmaceuticals Announces Phase II US-Based Diagnostic Cu SAR-Bombesin

New minor risk - Profitability

Clarity Pharmaceuticals Announces Positive Guidance from US FDA on Cu-64 Sar-Bispsma Phase III Trial in Prostate Cancer

Less than half of directors are independent

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies